{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:19:37Z","timestamp":1792657177006,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12020-020-02272-x","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:02:52Z","timestamp":1585699372000},"page":"504-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"69","author":[{"given":"Giovanni Antonio","family":"Silverii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Dicembrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Besmir","family":"Nreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Montereggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-828X","authenticated-orcid":false,"given":"Matteo","family":"Monami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"issue":"8","key":"2272_CR1","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.autrev.2019.06.007","volume":"18","author":"K Kridin","year":"2019","unstructured":"K. Kridin, D. Kneiber, E.H. Kowalski, M. Valdebran, K.T. Amber, Epidermolysis bullosa acquisita: a comprehensive review. Autoimmun. Rev. 18(8), 786\u2013795 (2019)","journal-title":"Autoimmun. Rev."},{"issue":"3","key":"2272_CR2","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1001\/archderm.1996.03890270044006","volume":"132","author":"S Bastuji-Garin","year":"1996","unstructured":"S. Bastuji-Garin, P. Joly, C. Picard-Dahan, P. Bernard, L. Vaillant, C. Pauwels et al. Drugs associated with bullous pemphigoid. A case-control study. Arch. Dermatol. 132(3), 272\u2013276 (1996)","journal-title":"Arch. Dermatol."},{"issue":"1","key":"2272_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","volume":"149","author":"A Lloyd-Lavery","year":"2013","unstructured":"A. Lloyd-Lavery, C.C. Chi, F. Wojnarowska, K. Taghipour, The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 149(1), 58\u201362 (2013)","journal-title":"JAMA Dermatol."},{"issue":"2","key":"2272_CR4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjd.15195","volume":"176","author":"CW Tan","year":"2017","unstructured":"C.W. Tan, Y. Pang, B. Sim, T. Thirumoorthy, S.M. Pang, H.Y. Lee, The association between drugs and bullous pemphigoid. Br. J. Dermatol. 176(2), 549\u2013551 (2017)","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"2272_CR5","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","volume":"175","author":"J Bene","year":"2016","unstructured":"J. Bene, G. Moulis, I. Bennani, M. Auffret, P. Coupe, S. Babai et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance database. Br. J. Dermatol. 175(2), 296\u2013301 (2016)","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"2272_CR6","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1080\/14740338.2019.1668373","volume":"18","author":"C Carnovale","year":"2019","unstructured":"C. Carnovale, F. Mazhar, E. Arzenton, U. Moretti, M. Pozzi, G. Mosini, et al. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic\/pharmacokinetic assessment through an analysis of the vigibase(R). Expert Opin. Drug Saf. 18(11), 1099\u20131108 (2019)","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"2272_CR7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ijd.14658","volume":"59","author":"A Reolid","year":"2019","unstructured":"A. Reolid, E. Munoz-Aceituno, P. Rodriguez-Jimenez, E. Gonzalez-Rojano, M. Llamas-Velasco, J. Fraga, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database. Int. J. Dermatol. 59(2), 197\u2013206 (2019)","journal-title":"Int. J. Dermatol."},{"issue":"6","key":"2272_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","volume":"78","author":"M Benzaquen","year":"2018","unstructured":"M. Benzaquen, L. Borradori, P. Berbis, S. Cazzaniga, R. Valero, M.A. Richard et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J. Am. Acad. Dermatol. 78(6), 1090\u20131096 (2018)","journal-title":"J. Am. Acad. Dermatol."},{"issue":"8","key":"2272_CR9","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.2337\/dc19-0409","volume":"42","author":"A Douros","year":"2019","unstructured":"A. Douros, J. Rouette, H. Yin, O.H.Y. Yu, K.B. Filion, L. Azoulay, Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabet. Care 42(8), 1496\u20131503 (2019)","journal-title":"Diabet. Care"},{"issue":"1","key":"2272_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-017-0219-x","volume":"17","author":"SH Lee","year":"2017","unstructured":"S.H. Lee, I. Gantz, E. Round, M. Latham, E.A. O\u2019Neill, P. Ceesay et al. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin. BMC Endocr. Disord. 17(1), 70 (2017)","journal-title":"BMC Endocr. Disord."},{"issue":"7","key":"2272_CR11","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","volume":"138","author":"O Varpuluoma","year":"2018","unstructured":"O. Varpuluoma, A.K. Forsti, J. Jokelainen, M. Turpeinen, M. Timonen, L. Huilaja et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J. Investig. Dermatol. 138(7), 1659\u20131661 (2018)","journal-title":"J. Investig. Dermatol."},{"key":"2272_CR12","doi-asserted-by":"publisher","unstructured":"K. Kridin, A. D. Cohen, Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J. Am. Acad. Dermatol. (2018) https:\/\/doi.org\/10.1016\/j.jaad.2018.09.048 (Epub-ahead of print)","DOI":"10.1016\/j.jaad.2018.09.048"},{"issue":"6","key":"2272_CR13","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S0190-9622(84)70266-0","volume":"11","author":"TY Chuang","year":"1984","unstructured":"T.Y. Chuang, W. Korkij, K. Soltani, J. Clayman, J. Cook, Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case-control study. J. Am. Acad. Dermatol. 11(6), 1099\u20131102 (1984)","journal-title":"J. Am. Acad. Dermatol."},{"key":"2272_CR14","doi-asserted-by":"crossref","unstructured":"D. Moher, A. Liberati, J. Tetzlaff, D.G.J.Aoim. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.151(4), 264\u2013269 (2009)","DOI":"10.7326\/0003-4819-151-4-200908180-00135"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-020-02272-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-020-02272-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T23:22:36Z","timestamp":1617146556000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-020-02272-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["2272"],"URL":"https:\/\/doi.org\/10.1007\/s12020-020-02272-x","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,31]]},"assertion":[{"value":"4 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"G.A.S and I.D have received speaking fees from Astra Zeneca, Novonordisk; C.M has no conflict of interest; B.N is presently employee of Novo Nordisk; M.M has received speaking fees from Astra Zeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli-Lilly, Merck, Novo Nordisk, Sanofi, and Novartis and research grants from Bristol Myers Squibb; E.M has received consultancy fees from Merck and Novartis speaking fees from Astra Zeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli-Lilly, Merck, Novo Nordisk, Sanofi, and Novartis and research grants from Merck, Novartis, and Takeda. All the authors approved the final version of this paper. M.M is the person who takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}